Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316814 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Momoko Gyoten und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Antineoplastic Agents, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, MEXT KAKENHI.
Abstract (Originalsprache)
Resistance to anticancer drugs is a problem in the treatment of pancreatic ductal carcinoma (PDAC) and overcoming it is an important issue. Recently, it has been reported that statins induce apoptosis in cancer cells but the mechanism has not been completely elucidated. We investigated the antitumor mechanisms of statins against PDAC and their impact on resistance to gemcitabine (GEM). Lovastatin (LOVA) increased mitochondrial oxidative stress in PDAC cells, leading to apoptosis. LOVA reduced lipid rafts in the plasma membrane and mitochondria, suppressed the activation of epithelial growth factor receptor (EGFR) and AKT in plasma membrane rafts, and reduced B-cell lymphoma 2 (BCL2)-Bcl-2-associated X protein (BAX) binding and the translocation of F1F0 ATPase in mitochondrial rafts. In the three GEM-resistant cell lines derived from MIA and PANC1, the lipid rafts in the cell membrane and the mitochondria were increased to activate EGFR and AKT and to increase BCL2-BAX binding, which suppressed apoptosis. LOVA abrogated these anti-apoptotic effects by reducing the rafts in the resistant cells. By treating the resistant cells with LOVA, GEM sensitivity improved to the level of the parental cells. Therefore, cholesterol rafts contribute to drug resistance in PDAC. Further clinical research is warranted on overcoming anticancer drug resistance by statin-mediated intracellular cholesterol regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
- Jiangsu Province Key Laboratory of Neuroregeneration, Nantong University, 19 Qixiu Road, Nantong 226001, China.
- Research Institute, Nozaki Tokushukai Hospital, 2-10-50 Tanigawa, Daito 574-0074, Osaka, Japan.
ORCID-Profile: Hiroki Kuniyasu
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- MEXT KAKENHI
Zitieren
APA
Gyoten, M., Luo, Y., Fujiwara-Tani, R., Mori, S., Ogata, R., Kishi, S., & Kuniyasu, H. (2023). Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316814
Vancouver
Gyoten M, Luo Y, Fujiwara-Tani R, Mori S, Ogata R, Kishi S, et al. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316814
BibTeX
@article{Gyoten2023,
author = {Gyoten, Momoko and Luo, Yi and Fujiwara-Tani, Rina and Mori, Shiori and Ogata, Ruiko and Kishi, Shingo and Kuniyasu, Hiroki},
title = {Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316814}
}
EUVIMED